JP6044831B2 - 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 - Google Patents
膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 Download PDFInfo
- Publication number
- JP6044831B2 JP6044831B2 JP2012534113A JP2012534113A JP6044831B2 JP 6044831 B2 JP6044831 B2 JP 6044831B2 JP 2012534113 A JP2012534113 A JP 2012534113A JP 2012534113 A JP2012534113 A JP 2012534113A JP 6044831 B2 JP6044831 B2 JP 6044831B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vaginosis
- compound
- salt
- vaginal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 52
- 150000003839 salts Chemical class 0.000 title claims description 45
- 239000004480 active ingredient Substances 0.000 title claims description 8
- 230000002265 prevention Effects 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 48
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 21
- 239000008103 glucose Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 208000004926 Bacterial Vaginosis Diseases 0.000 claims description 14
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 12
- 208000037009 Vaginitis bacterial Diseases 0.000 claims description 12
- 238000004140 cleaning Methods 0.000 claims description 10
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 9
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 239000000003 vaginal tablet Substances 0.000 claims description 7
- 229940044977 vaginal tablet Drugs 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- -1 glucose compound Chemical class 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 210000001215 vagina Anatomy 0.000 description 9
- 206010046914 Vaginal infection Diseases 0.000 description 7
- 230000000844 anti-bacterial effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 201000008100 Vaginitis Diseases 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 241000207202 Gardnerella Species 0.000 description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 2
- 241000203736 Mobiluncus Species 0.000 description 2
- 241000204051 Mycoplasma genitalium Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 241000224527 Trichomonas vaginalis Species 0.000 description 2
- 241000202898 Ureaplasma Species 0.000 description 2
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 241000902900 cellular organisms Species 0.000 description 2
- 210000003756 cervix mucus Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000000644 isotonic solution Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960003085 meticillin Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000021962 pH elevation Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000007143 thioglycolate medium Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- JWDYCNIAQWPBHD-UHFFFAOYSA-N 1-(2-methylphenyl)glycerol Chemical compound CC1=CC=CC=C1OCC(O)CO JWDYCNIAQWPBHD-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241001512723 Ecklonia Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241001324870 Lactobacillus iners Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000605894 Porphyromonas Species 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000459 effect on growth Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000004172 quinoline yellow Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 208000013464 vaginal disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
1−1.融解塩の調製
900mgの天然塩(シナン、大韓民国、www.nhshinansalt.com)を、加熱器(MS−E104、TOPS Co. Ltd.)を用いて850−1000℃にて24時間融解させて、400mgの融解塩を得た。
400mgの純粋塩(NaCl、F.W.58.44)を、商社(SPPO−91701、Duksan company、www.duksan.co.kr)から購入した。
800mgのブドウ糖(結晶ブドウ糖)を、商社(Samyang genex Corp.,www.genex.co.kr)から購入した。
上記の段階によって調製した400mgの融解塩および800mgのブドウ糖を完全に混合して、1200mgの発明化合物(以下「SG1」と表す)を得た。
上記の段階によって調製した400mgの純塩および800mgのブドウ糖を完全に混合して、1200mgの発明化合物(以下「SG4」と表す)を得た。
400mgの融解塩および800mgのブドウ糖から成る実施例1で調製した化合物を2mgのステアリン酸マグネシウムと混合し、錠剤化装置(KT2000、Kumsungkigong Co. Ltd)を用いて発明の膣錠剤組成物(以下「SG2」と表す)に製剤化した。
400mgの純塩および800mgのブドウ糖から成る実施例1で調製した化合物を含む膣洗浄溶液組成物を、表1に示す以下の成分と混合し、48時間撹拌して調製した(以下「SG3」と表す)。
SG3溶液(100ml)
1−1.実験株
以下の試験では、(1)アシドフィルス菌株(KRIBB寄託番号:KCTC 1120)および(2)ガードネレラ・バジナリス株(KRIBB寄託番号:KCTC 5096)の2株を、KCTC(KRIBB(大韓民国生命工学研究院)の遺伝子銀行)から調達し、嫌気パウチ法(GasPak(登録商標)、EZ Pouch System)に従って、液体培地(チオグリコレート培地、DIFCO(登録商標))において37℃で、または固体培地(血液寒天培地)において37℃で培養した。
実施例1において調製した発明化合物(SG1)を試験試料として使用し、乳酸(Fluka Co.,ACS試薬、85−90%、L−乳酸/水)を実験に使用した。
実施例1において調製した発明化合物(SG1)のラクトバチルス・アシドフィルス(Lactobacillus acidophilus)の成長に対する効果を試験するために、文献(Choi,J.G.ら、Antibacterial activity of Ecklonia cava against methicillin−resitant Staphylococcus aureus and Salmonella spp.,Foodborne Pathog.Dis.,2010(Apr.):7(4),pp435−441)に開示の手順に従って以下の試験を実施した。
実施例1において調製した発明化合物(SG1)の、膣症の主因であるガードネレラ・バジナリス株の成長に対する効果を試験するために、文献(Choi,J.G.ら、Antibacterial activity of Hylomecon hylomeconoides against methicillin−resitant Staphylococcus aureus,Appl.Biochem.Biotechnol.,2010(Apr.):160(8),pp2467−2474)に開示の手順に従って以下のディスク拡散試験を実施した。
ガードネレラ・バジナリス株の成長に対する効果
大韓民国に在住の20歳〜50歳の範囲における、膣症を患う35人の患者および65人の正常な女性から成る100人のボランティアに、実施例2で調製した1200mgの膣錠剤組成物(SG2)を1日に1回5日間膣内に投与し、発明組成物の効果において直接的な調査を実施した。
大韓民国に在住の20歳〜50歳の範囲における、膣症を患う42人の患者および58人の正常な女性から成る100人のボランティアに、実施例3で調製した200mlの膣洗浄組成物(SG3)を膣の洗浄のために1日に1回5日間外部から投与し、発明組成物を用いた治療の(A)前と(B)後の間における膣のpHの相違をpHメーター(MP−103、www.yuyuinst.co.kr)を用いて決定した。
pHの相違
Claims (3)
- ガードネレラ・バジナリス(Gardnerella vaginalis)に起因する細菌性膣炎を、ラクトバチルス・アシドフィルス(Lactobacillus acidophilus)を増殖させることで、治療するために、薬学的に許容される担体と共に有効量の融解NaCl、およびブドウ糖の化合物を有効成分として含む組成物であって、
前記融解NaCl、およびブドウ糖の化合物は、1:1−3(w/w)の比率で混合され、
前記融解NaClが、天然塩を原料とし融解温度が800〜1000℃で融解時間が12時間以上48時間以下である融解NaClであることを特徴とする、
皮膚外用組成物。 - 請求項1に記載の組成物であって、該組成物は膣錠剤組成物または洗浄液組成物である組成物。
- 薬剤の製造における、融解NaCl、およびブドウ糖の化合物を有効成分として含む使用方法であって、
前記融解NaCl、およびブドウ糖の化合物は、1:1−3(w/w)の比率で混合され、
前記薬剤は哺乳動物におけるガードネレラ・バジナリス(Gardnerella vaginalis)に起因する細菌性膣炎を、ラクトバチルス・アシドフィルス(Lactobacillus acidophilus)を増殖させることで、治療することを目的とし、
前記融解NaClは、天然塩を800〜1000℃の範囲の温度にて12時間〜48時間の間融解させて調製されることを特徴とする、
使用方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20090099333 | 2009-10-19 | ||
KR10-2009-0099333 | 2009-10-19 | ||
KR1020100097774A KR101133723B1 (ko) | 2009-10-19 | 2010-10-07 | 소금 및 당을 유효성분으로 함유하는 질염 예방 및 치료용 조성물 및 이의 용도 |
KR10-2010-0097774 | 2010-10-07 | ||
PCT/KR2010/007068 WO2011049327A2 (en) | 2009-10-19 | 2010-10-15 | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016172680A Division JP6429131B2 (ja) | 2009-10-19 | 2016-09-05 | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013508269A JP2013508269A (ja) | 2013-03-07 |
JP2013508269A5 JP2013508269A5 (ja) | 2016-11-17 |
JP6044831B2 true JP6044831B2 (ja) | 2016-12-14 |
Family
ID=44048707
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012534113A Active JP6044831B2 (ja) | 2009-10-19 | 2010-10-15 | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 |
JP2016172680A Active JP6429131B2 (ja) | 2009-10-19 | 2016-09-05 | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016172680A Active JP6429131B2 (ja) | 2009-10-19 | 2016-09-05 | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 |
Country Status (14)
Country | Link |
---|---|
US (2) | US20120201904A1 (ja) |
EP (2) | EP3192516A1 (ja) |
JP (2) | JP6044831B2 (ja) |
KR (1) | KR101133723B1 (ja) |
CN (1) | CN102573858B (ja) |
AU (1) | AU2010308741B2 (ja) |
BR (1) | BR112012008470A2 (ja) |
CA (1) | CA2778371C (ja) |
HK (1) | HK1167348A1 (ja) |
MX (1) | MX2012004509A (ja) |
MY (1) | MY182983A (ja) |
NZ (1) | NZ599265A (ja) |
RU (1) | RU2536264C2 (ja) |
WO (1) | WO2011049327A2 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9433641B2 (en) * | 2009-10-19 | 2016-09-06 | Won Seog Choi | Skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof |
JP5547123B2 (ja) * | 2011-03-30 | 2014-07-09 | 株式会社 資生堂 | 油中水型乳化化粧料 |
KR101470282B1 (ko) * | 2013-10-01 | 2014-12-05 | 최원석 | 소금 및 당의 조합물을 유효성분으로 함유하는 질이완증 또는 질건조증 예방 및 치료용 약학 조성물 및 이의 용도 |
CN108235682A (zh) | 2015-09-29 | 2018-06-29 | 金伯利-克拉克环球有限公司 | 用于维护微生物群落的健康平衡的协同组合物 |
KR101784847B1 (ko) * | 2016-05-10 | 2017-10-13 | 주식회사 하우동천 | 질염 예방 및 치료용 유산균 함유 조성물 및 이의 용도 |
KR101771479B1 (ko) | 2016-12-23 | 2017-09-05 | 유한회사 아이에스티케이3 | 천연식물추출물 및 당을 유효성분으로 함유하는 질염예방 및 치료용 조성물 |
MX2019008782A (es) | 2017-02-28 | 2019-10-02 | Kimberly Clark Co | Composicion sinergica para el mantenimiento del equilibrio saludable de la microflora. |
KR102091440B1 (ko) * | 2018-07-26 | 2020-03-20 | 이기용 | 질 세정제를 이용한 질 세정용 위생용품 |
RU2726123C1 (ru) * | 2019-12-20 | 2020-07-09 | Федеральное государственное бюджетное учреждение науки Оренбургский федеральный исследовательский центр Уральского отделения Российской академии наук | Способ лечения трихомониаза у женщин |
KR102285430B1 (ko) | 2020-01-06 | 2021-08-04 | 주식회사 벤스랩 | 염화칼륨을 포함하는 여성세정제 조성물 |
KR102213286B1 (ko) | 2020-07-31 | 2021-02-05 | 정소영 | 질염의 치료 및 자궁경부이형성증의 예방용 한약 조성물 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2823163A (en) * | 1956-10-11 | 1958-02-11 | Richard K Thoms | Antivaginitis process and cation exchange resin composition |
IT1172185B (it) * | 1981-12-21 | 1987-06-18 | Serono Ist Farm | Composizione particolarmente per la vande vaginali |
DE3232136A1 (de) * | 1982-08-28 | 1984-03-01 | Ruth Cegla GmbH, 7542 Schömberg | Gemisch enthaltend meersalz und/oder salinensalz |
SE8603338D0 (sv) * | 1986-08-07 | 1986-08-07 | Bjorn Andersch | Medel for behandling av tillstand i slidan |
US5098709A (en) * | 1987-07-21 | 1992-03-24 | Kang Kwon J | Method of administrating a fused salt from natural substances, namely ginkgo, persimmon, pine, and bamboo in the treatment of inflammations |
HU212426B (en) * | 1992-07-22 | 1996-06-28 | Vepex Kft | Process for producing bioactive pharmaceutical compositions |
AU675304B2 (en) * | 1993-06-04 | 1997-01-30 | Senju Pharmaceutical Co., Ltd. | Ophthalmic topical agent |
US5916176A (en) * | 1994-08-25 | 1999-06-29 | Caillouette; James C. | Estrogen or estradiol need determination by vaginal or urethral acidity determination |
CA2256365A1 (en) * | 1996-05-22 | 1997-11-27 | Diversified Pharmaceuticals, Inc. | Compositions, methods and devices for the transdermal delivery of drugs |
ATE306274T1 (de) * | 1997-11-24 | 2005-10-15 | Zhongming Zeng | Verwendung von dextrin, stärke oder glykogen zur behandlung von bakterieller vaginosis |
KR20010029068A (ko) * | 1999-09-29 | 2001-04-06 | 강권중 | 죽염과 운모를 유효성분으로 함유하는 질정제 |
RU2234325C1 (ru) * | 2003-12-10 | 2004-08-20 | ЗАО "Аэромед" | Способ лечения заболеваний влагалища и устройство для его осуществления (варианты) |
CN100389763C (zh) * | 2004-02-10 | 2008-05-28 | 周世兰 | 改善妇女阴道酸、湿性的乳酸、甘油制剂 |
SE528337C2 (sv) * | 2004-06-23 | 2006-10-24 | Nestor Medical Ab | Sammansättning innefattande mjölksyra och laktoferrin, eller ett peptidfragment därav, och användning av denna sammansättning för behandling av tillstånd i urogenitalsystemet |
US20080286384A1 (en) * | 2004-09-15 | 2008-11-20 | Renee Reichert | Topical Wound Care Product Containing Hyssop |
US7619008B2 (en) * | 2004-11-12 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Xylitol for treatment of vaginal infections |
JP5065246B2 (ja) * | 2005-04-27 | 2012-10-31 | シェンジェン フールオ バイオテクノロジー リミテッド | 腟の微生物叢と腟の酸性を調節して維持する組成物と方法 |
EP2099309A4 (en) * | 2006-01-24 | 2014-04-30 | Fjell & Fjord Mat As | COMPOSITION COMPRISING SUGAR AND SALT FOR THE TREATMENT OF MEAT |
JP5199551B2 (ja) * | 2006-07-06 | 2013-05-15 | サンスター株式会社 | カンジダ菌感染に基づく疾患の予防又は改善剤 |
CN101530403A (zh) * | 2008-03-14 | 2009-09-16 | 郭进军 | 用于治疗或预防妇女阴道炎、宫颈糜烂的木糖醇组合物 |
CN101797269B (zh) * | 2010-03-23 | 2012-01-04 | 杨霞 | 一种调节女性阴道微生态的生理平衡液 |
-
2010
- 2010-10-07 KR KR1020100097774A patent/KR101133723B1/ko active IP Right Review Request
- 2010-10-15 EP EP17159197.7A patent/EP3192516A1/en not_active Withdrawn
- 2010-10-15 MY MYPI2012001746A patent/MY182983A/en unknown
- 2010-10-15 MX MX2012004509A patent/MX2012004509A/es active IP Right Grant
- 2010-10-15 EP EP10825152.1A patent/EP2490700A4/en not_active Ceased
- 2010-10-15 RU RU2012113101/15A patent/RU2536264C2/ru active
- 2010-10-15 US US13/501,910 patent/US20120201904A1/en not_active Abandoned
- 2010-10-15 CN CN2010800466317A patent/CN102573858B/zh active Active
- 2010-10-15 WO PCT/KR2010/007068 patent/WO2011049327A2/en active Application Filing
- 2010-10-15 BR BR112012008470A patent/BR112012008470A2/pt not_active Application Discontinuation
- 2010-10-15 JP JP2012534113A patent/JP6044831B2/ja active Active
- 2010-10-15 NZ NZ599265A patent/NZ599265A/en unknown
- 2010-10-15 CA CA2778371A patent/CA2778371C/en active Active
- 2010-10-15 AU AU2010308741A patent/AU2010308741B2/en active Active
-
2012
- 2012-08-22 HK HK12108229.2A patent/HK1167348A1/xx unknown
-
2013
- 2013-09-12 US US14/025,698 patent/US20140037758A1/en not_active Abandoned
-
2016
- 2016-09-05 JP JP2016172680A patent/JP6429131B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20120201904A1 (en) | 2012-08-09 |
MX2012004509A (es) | 2012-06-04 |
CA2778371A1 (en) | 2011-04-28 |
JP2013508269A (ja) | 2013-03-07 |
CN102573858A (zh) | 2012-07-11 |
AU2010308741A1 (en) | 2012-05-03 |
WO2011049327A3 (en) | 2011-10-20 |
EP3192516A1 (en) | 2017-07-19 |
KR101133723B1 (ko) | 2012-04-09 |
AU2010308741B2 (en) | 2015-02-19 |
NZ599265A (en) | 2014-03-28 |
JP2017025078A (ja) | 2017-02-02 |
RU2012113101A (ru) | 2013-11-27 |
WO2011049327A2 (en) | 2011-04-28 |
CA2778371C (en) | 2017-09-05 |
EP2490700A2 (en) | 2012-08-29 |
US20140037758A1 (en) | 2014-02-06 |
CN102573858B (zh) | 2013-09-18 |
RU2536264C2 (ru) | 2014-12-20 |
EP2490700A4 (en) | 2013-08-07 |
MY182983A (en) | 2021-02-05 |
BR112012008470A2 (pt) | 2016-04-05 |
JP6429131B2 (ja) | 2018-11-28 |
HK1167348A1 (en) | 2012-11-30 |
KR20110043448A (ko) | 2011-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6429131B2 (ja) | 膣症を予防および治療するために塩および糖を有効成分として含む皮膚外用組成物およびその使用 | |
EP3520785B1 (en) | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use | |
EP3139939B1 (en) | Compositions and methods for treating skin and mucous membrane diseases | |
CN102470117B (zh) | 一种以苯甲酸和有机酸防腐剂相联合作为有效成分的组合物及其用途 | |
JP2020516684A (ja) | 炎症及び炎症性疾患の治療法 | |
JP2009269922A (ja) | 微生物感染を予防または制御するための共生Bacillus芽胞の局所的使用 | |
CN109985069B (zh) | 益生菌组合物及其用途 | |
JP2022504792A (ja) | 炎症性疾患及び関連する感染の治療方法 | |
CN111449973A (zh) | 一种修复女性阴道微生态平衡的泡沫剂及其制备方法 | |
JP2020525460A (ja) | 皮膚科治療におけるガラクトオリゴ糖およびキシリトールの抗菌活性 | |
US20040110721A1 (en) | Pharmaceutical compositions for promoting the growth of gram-positive bacilli and increasing the acidity in the vagina and the use thereof | |
ES2532884T3 (es) | Composición vaginal a base de alquilpoliglucósidos | |
US9408868B2 (en) | Skin external composition comprising a combination of sodium chloride and glucose as active ingredients for treating vaginosis and the use thereof | |
KR102203849B1 (ko) | 동물용 복합 항생제 조성물 | |
DE102017113263A1 (de) | Pharmazeutische Zusammensetzung enthaltend Bakterienstämme aus der Familie der Lactobacillaceae und Molke | |
US9446069B2 (en) | Skin external composition comprising a sea salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
CN111588773B (zh) | 通过母猪服药防治新生仔猪腹泻的中药组合物及其应用 | |
KR102342160B1 (ko) | 탁시폴린을 포함하는 바이오필름 형성 억제용 조성물 | |
CN110664879A (zh) | 一种人参茎叶总皂苷阴道膨胀栓及其制备方法和应用 | |
JP2023526043A (ja) | 細菌株を含む組成物、ならびに眼の疾患および病変の処置のための同組成物の使用 | |
Tarasenko et al. | Modern methods for sanitation of pleural cavity in patients with nonspecific pleural empyema |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130918 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140722 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141021 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141121 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141222 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150804 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151026 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20151130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20160905 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161025 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161102 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6044831 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |